Focus
Cell Therapy Investors: Angels and VC Firms
The RaiseHunt database lists 146 Cell Therapy investors: 11 angel investors and 135 people at 42 firms. Most list Seed and Series B among their stages; the largest hubs are San Francisco, New York and London.
Strongest in San Francisco, New York and London
- 146
- Cell Therapy investors
- 11
- Angel investors
- 135
- People at VC/PE firms
- 42
- Firms tagged
Skip the browsing. Let AI find your ideal investors in one minute.
Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.
146 Cell Therapy investors
Showing 1-20
| Investor | Location | Type | Markets | Contact | Actions |
|---|---|---|---|---|---|
Larry Lasky Investor at The Column Group | Sausalito, United States | Venture capital | Healthcare | View profile | |
Tim Bliss Investor Relations & Finance at Teva Pharmaceuticals | United States | Corporate VC | Healthcare | View profile | |
Minglin Ma Executive Director at Vertex Pharmaceuticals | Ithaca, United States | Corporate VCFamily Office | AIClimate | View profile | |
Jeff Goater Partner at The Column Group | Boston, United States | Venture capital | Healthcare | View profile | |
Anthony Arceci Biotech Investor at 5AM Ventures | Boston, United States | Venture capital | Healthcare | View profile | |
Carla Daniel Partner & Chief People Officer at The Column Group | San Francisco, United States | Venture capital | Healthcare | View profile | |
Kush Parmar Managing Partner at 5AM Ventures | Boston, United States | Venture capital | Healthcare | View profile | |
Max Farina Principal at 5AM Ventures | San Francisco, United States | Venture capital | Healthcare | View profile | |
John Prufeta Founder & General Partner at Medical Excellence Capital | New York City, United States | Venture capital | Healthcare | View profile | |
Leon Chen Partner at The Column Group | Palo Alto, United States | Venture capital | Healthcare | View profile | |
Sarah Hymowitz Partner at The Column Group | San Francisco, United States | Venture capital | Healthcare | View profile | |
Joni Mancini Managing Partner at Medical Excellence Capital | Manhasset, United States | Venture capital | Healthcare | View profile | |
Bill Fisher Senior Consultant at Celgene | Chattanooga, United States | Corporate VC | Healthcare | View profile | |
Brian Halak Managing Partner at Medical Excellence Capital | Wayne, United States | Corporate VCVenture capital | AIHealthcare | View profile | |
John Josey Partner at The Column Group | Dallas, United States | Venture capital | Healthcare | View profile | |
Kim Kamdar Managing Partner at Medical Excellence Capital | San Diego, United States | Venture capital | Healthcare | View profile | |
Michael Rape Investigator at Howard Hughes Medical Institute (HHMI) | San Francisco, United States | Family OfficeVenture capital | EducationHardware | View profile | |
Zeev Zehavi Vice President at Teva Pharmaceuticals | Petah Tikva, Israel | Corporate VC | Healthcare | View profile | |
Donghong wu Investor at Witruth Capital | Beijing, China | Family OfficePrivate equity | Healthcare | View profile | |
John wu Investor at Witruth Capital | Beijing, China | Family OfficePrivate equity | Healthcare | View profile |
106 of 146 Cell Therapy investors, A to Z
Grouped by first letter. Name and profile link only, the detailed rows are in the table above.ShowHide
A10
- Abraham Bassan
- Aditya Asokan
- Alan Barge
- Alexander Munoz
- Alexis Ji
- Amit Shah
- Andrew Bartynski
- Andy Schwab
- Arie Belldegrun
- Arturo Urrios
B3
- Birthe R.
- Brian Daniels
- Brian Kickham
C1
- Chong Yoon Rha
D4
- David Goeddel
- David Goeddel
- David Parry
- Deborah Palestrant
E3
- Egen Atkinson
- Eric Heil
- Erika Lakos
F1
- Florian Alexander Bettin
G4
- George Seabridge
- Gregory A Bonfiglio
- Guillem Laporta
- Gunaretnam Rajagopal
H4
- Hao Wu
- Heath Lukatch
- Hiroko Kimura
- Hui Tian
I1
- Iñigo López-Huerta Anitua
J19
- Jake Nunn
- Jake Rhyner
- Jalal Taleb
- Jeremy Caldwell
- Jesse Dong
- Jian Wang
- Jiazhen Chen
- Jill Carroll
- Joël Jean-Mairet
- John Diekman
- John Diekman
- Jonathan Hay
- Jordi Xiol
- Joseph Victor
- Joshua Kennedy-Smith
- Julia Salaverria
- Jung Hyun Kim
- Justin Xiang
- Juyeol Choe
K4
- Karen Wagner
- Karimah Es Sabar
- Katie Bodner Spielberg
- Koji Yasuda
L4
- Lauren Cujé
- Lisa Schechner
- Logan Brock
- Long Tang
M10
- Marcos Milla
- Marietta Wu
- Martin Blüggel
- Michael Diem
- Michael Kramarz
- Mike Dybbs
- Mike Rice
- Milesh Patel
- Millie Ray
- Mitchell Mutz
N4
- Nate Tower
- Nathan Fischel
- Naveen Yalamanchi
- Niklas Prager
O1
- Olav Carlsen
P8
- Patricia Ledecky
- Patrick Doyle
- Paul Lu
- Perry Nisen
- Peter Fong
- Peter Svennilson
- Philip Habib
- Piratip Pratumsuwan
Q1
- Qinda Ye
R9
- Rajeev Dadoo
- Rathnam Venkat
- Raúl Martín-Ruiz
- Rick Klausner
- Robert Baffi
- Roderick Wong
- Roger Kang
- Rosie Barnett
- Ruize
S9
- Scott Rocklage
- Seamus Mulligan
- Shun Asami
- Shunsuke Nakaji
- Srini Akkaraju
- Stella Xu
- Stephanie A. Sirota
- Stephen Shuttleworth
- Steve Schmidt
T3
- Tim Kutzkey
- Ting Guo
- Tracy Ooi
Y1
- Yingying Yang
Z2
- Zafrira Avnur
- Zhanghang Yan
Frequently asked questions
How many Cell Therapy investors are on RaiseHunt?
RaiseHunt currently lists 146 Cell Therapy investors.
Are Cell Therapy investors angels or funds?
Both. 11 are angel investors putting in their own money, and 135 are people making investment decisions at 42 firms.
Where are most Cell Therapy investors based?
The largest concentrations are in San Francisco, New York and London.
What stage do Cell Therapy investors invest at?
Most list Seed and Series B among the rounds they take part in.
How do I contact Cell Therapy investors?
Every profile shows whether an email address is on file. The addresses themselves, along with AI matching and outreach, are in the RaiseHunt app.
Is the list of Cell Therapy investors free to browse?
Yes. The directory and every profile page are free to read. Matching your own startup against them requires an account.
Do Cell Therapy investors only back Cell Therapy companies?
No. A focus area is a signal of interest, not a restriction. Investors usually list several, and the useful question is whether their existing portfolio looks like the kind of company you are building.
What do investors look at first?
The team and the problem, in that order, before the product. Early on there is rarely enough traction to argue from numbers alone, so the question they are answering is whether these particular people are likely to work this problem out.
Should I raise from one investor or several?
Several, in almost every case. A single backer concentrates the risk of the round collapsing if that one conversation goes cold, and a group brings more introductions later. Rounds are usually assembled from a lead plus others who follow.
How do I follow up without being annoying?
Follow up with new information rather than a reminder. A short note saying what changed since you last wrote gives the reader a reason to reply, where "just checking in" gives them none. Two or three of those, spaced out, is normal and expected.
What if no Cell Therapy investor replies?
Usually the list was too short or too loosely matched, not that the company is unfundable. Widen it, tighten who you are writing to, and rewrite the first two lines of the message. Those lines decide whether anything below them gets read.
What is the difference between an angel investor and a VC fund?
An angel invests their own money and can decide alone, which usually makes the process shorter. A fund invests money it raised from other people, so it answers to those backers and normally runs a longer diligence process before it commits. Founders often raise from angels first and bring in a fund once there is more to show.
Data: RaiseHunt investor dataset · Snapshot 27 August 2026 · How this data is built · Report a correction or request removal
